Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States

Paschalis Vergidis, Raymund R. Razonable, L. Joseph Wheat, Lynn Estes, Angela M. Caliendo, Lindsey R. Baden, John R. Wingard, John Baddley, Maha Assi, Steven Norris, Pranatharthi Chandrasekar, Ryan Shields, Hong Nguyen, Alison Freifeld, Richard Kohler, Martin Kleiman, Thomas J. Walsh, Chadi Hage

Research output: Contribution to journal › Article

32 Citations (Scopus)

Abstract

Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) wa.

Original languageEnglish
Pages (from-to)2199-2201
Number of pages3
JournalJournal of Clinical Microbiology
Volume52
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Aspergillus
Immunoenzyme Techniques
Serum
galactomannan
tazobactam drug combination piperacillin

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. / Vergidis, Paschalis; Razonable, Raymund R.; Wheat, L. Joseph; Estes, Lynn; Caliendo, Angela M.; Baden, Lindsey R.; Wingard, John R.; Baddley, John; Assi, Maha; Norris, Steven; Chandrasekar, Pranatharthi; Shields, Ryan; Nguyen, Hong; Freifeld, Alison; Kohler, Richard; Kleiman, Martin; Walsh, Thomas J.; Hage, Chadi.

In: Journal of Clinical Microbiology, Vol. 52, No. 6, 2014, p. 2199-2201.

Research output: Contribution to journal › Article

Vergidis, P, Razonable, RR, Wheat, LJ, Estes, L, Caliendo, AM, Baden, LR, Wingard, JR, Baddley, J, Assi, M, Norris, S, Chandrasekar, P, Shields, R, Nguyen, H, Freifeld, A, Kohler, R, Kleiman, M, Walsh, TJ & Hage, C 2014, 'Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States', Journal of Clinical Microbiology, vol. 52, no. 6, pp. 2199-2201. https://doi.org/10.1128/JCM.00285-14
Vergidis P, Razonable RR, Wheat LJ, Estes L, Caliendo AM, Baden LR et al. Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. Journal of Clinical Microbiology. 2014;52(6):2199-2201. https://doi.org/10.1128/JCM.00285-14
Vergidis, Paschalis ; Razonable, Raymund R. ; Wheat, L. Joseph ; Estes, Lynn ; Caliendo, Angela M. ; Baden, Lindsey R. ; Wingard, John R. ; Baddley, John ; Assi, Maha ; Norris, Steven ; Chandrasekar, Pranatharthi ; Shields, Ryan ; Nguyen, Hong ; Freifeld, Alison ; Kohler, Richard ; Kleiman, Martin ; Walsh, Thomas J. ; Hage, Chadi. / Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. In: Journal of Clinical Microbiology. 2014 ; Vol. 52, No. 6. pp. 2199-2201.
@article{b20b225cb7ae44129f1186bde543d555,
title = "Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States",
abstract = "Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7{\%}) wa.",
author = "Paschalis Vergidis and Razonable, {Raymund R.} and Wheat, {L. Joseph} and Lynn Estes and Caliendo, {Angela M.} and Baden, {Lindsey R.} and Wingard, {John R.} and John Baddley and Maha Assi and Steven Norris and Pranatharthi Chandrasekar and Ryan Shields and Hong Nguyen and Alison Freifeld and Richard Kohler and Martin Kleiman and Walsh, {Thomas J.} and Chadi Hage",
year = "2014",
doi = "10.1128/JCM.00285-14",
language = "English",
volume = "52",
pages = "2199--2201",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States

AU - Vergidis, Paschalis

AU - Razonable, Raymund R.

AU - Wheat, L. Joseph

AU - Estes, Lynn

AU - Caliendo, Angela M.

AU - Baden, Lindsey R.

AU - Wingard, John R.

AU - Baddley, John

AU - Assi, Maha

AU - Norris, Steven

AU - Chandrasekar, Pranatharthi

AU - Shields, Ryan

AU - Nguyen, Hong

AU - Freifeld, Alison

AU - Kohler, Richard

AU - Kleiman, Martin

AU - Walsh, Thomas J.

AU - Hage, Chadi

PY - 2014

Y1 - 2014

N2 - Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) wa.

AB - Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) wa.

UR - http://www.scopus.com/inward/record.url?scp=84901660357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901660357&partnerID=8YFLogxK

U2 - 10.1128/JCM.00285-14

DO - 10.1128/JCM.00285-14

M3 - Article

VL - 52

SP - 2199

EP - 2201

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 6

ER -

Access to Document